Silexion Therapeutics (SLXN)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Dagens Silexion Therapeutics Corp Ordinary Shares (SLXN) aktiekurs på after-hours är , vilket speglar en NaN % after-hours rörelse sedan marknaden stängde. Företagets marknadsvärde är 5,16 mn $, med en daglig handelsvolym på  aktier. Det tidigare stängningspriset var .

Redo att börja? Följ stegen nedan, eller läs vår guide om hur man köper Silexion Therapeutics aktier på Kraken med start från 10 $.